Table 4.
All withdrawals (n=80) | During a placebo period (n=39) | During a statin period (n=34) | Neither (n=7) | |
---|---|---|---|---|
Withdrawal of consent | 16 (8) | 8 (4) | 7 (3.5) | 1 (0.5) |
Muscle symptoms* | 1 (0.5) | 1 (0.5) | 0 | 0 |
Non-muscle symptoms* | 4 (2) | 2 (1) | 2 (1) | 0 |
Not related to drug treatment* | 3 (1.5) | 1 (0.5) | 2 (1) | 0 |
Switched to statin* | 0 | 0 | 0 | 0 |
No reason given* | 8 (4) | 4 (2) | 3 (1.5) | 1 (0.5) |
Intolerable muscle symptoms | 32 (16) | 13 (6.5) | 18 (9) | 1 (0.5) |
Clinical concern | 14 (7) | 9 (4.5) | 4 (2) | 1 (0.5) |
Muscle symptoms* | 1 (0.5) | 1 (0.5) | 0 | 0 |
Non-muscle symptoms* | 4 (2) | 2 (1) | 2 (1) | 0 |
Not related to drug treatment* | 5 (2.5) | 3 (1.5) | 2 (1) | 0 |
Switched to statin* | 4 (2) | 3 (1.5) | 0 (0) | 1 (0.5) |
Other | 17 (8.5) | 8 (4) | 5 (2.5) | 4 (2) |
Non-muscle symptoms* | 4 (2) | 4 (2) | 0 | 0 |
Not related to drug treatment* | 13 (6.5) | 4 (2) | 5 (2.5) | 4 (2) |
Unknown | 1 (0.5) | 1 (0.5) | 0 | 0 |
Data are number (%) of participants from 200 participants randomised to a sequence of treatments.
Post hoc finer categorisation.